Skip to main content
Alliance Equity Research
AER Insights
All insights
Biotechnology & Healthcare

Amylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment

Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.

6 min read
Conceptual image of an unbranded medicine vial and blood glucose meter.

Amylyx Pharmaceuticals has released a fuller account of a Phase 3 trial for avexitide, an investigational medicine for people who experience recurrent low blood sugar after gastric bypass. The company previously reported that the study met its primary endpoint. Its November 14 disclosure adds absolute event rates, patient characteristics and completion figures, giving investors a better view of the potential benefit and the population in which it was measured.

In the 16-week LUCIDITY study, the estimated rate of specified hypoglycemic events was 0.55 per week with avexitide and 1.24 with placebo, a 55% relative reduction. The result brings Amylyx closer to an FDA submission planned by the end of 2026. Its commercial opportunity will depend on the eventual label, physicians identifying affected patients and payers covering a daily injectable treatment.

Why blood sugar can fall after surgery

Post-bariatric hypoglycemia, or PBH, is recurrent low blood sugar that can develop after weight-loss surgery. After a meal, altered gastrointestinal anatomy can lead to an exaggerated release of the hormone GLP-1 and, in turn, insulin. Excess insulin can drive glucose too low, causing symptoms that range from shakiness and confusion to episodes requiring another person's assistance.

Avexitide is designed to block the GLP-1 receptor and reduce that excessive insulin response. This is a different use of the GLP-1 pathway from weight-loss drugs that stimulate it. Patients in LUCIDITY continued dietary management, an important part of current care, while receiving the study drug or placebo.

Amylyx acquired the avexitide assets from Eiger BioPharmaceuticals in 2024 for $35.1 million, plus specified cure costs and assumed liabilities. It is now building commercial and manufacturing capabilities ahead of a potential launch, if the medicine is approved.

What the trial measured

The November 14 trial disclosure describes 78 adults with PBH following Roux-en-Y gastric bypass. After a three-week run-in, participants were randomized 3:2 to avexitide 90 mg injected under the skin once daily or placebo. Both groups followed dietary management throughout the run-in and blinded treatment period.

The primary endpoint combined Level 2 events confirmed by self-monitoring of blood glucose with Level 3 events adjudicated by a blinded committee. Level 2 means glucose below 54 mg/dL; Level 3 describes an episode involving impaired mental or physical function that requires assistance from another person. The primary measure was an event rate, so a reduction does not mean the same percentage of patients became event-free.

LUCIDITY measureAvexitide compared with placebo
Primary composite Level 2/3 event rate0.55 versus 1.24 events per week
Relative reduction in composite rate55%; p=0.0000034
Self-monitored Level 2 event rate63% lower; p=0.0000032
Adjudicated Level 3 event rate47% lower; p=0.0016
Continuous-monitoring Level 2 event rate42% lower; p=0.00016

The absolute primary rates are model-based least-squares means, not raw counts. Their difference is approximately 0.69 events per week, a useful measure of scale alongside the relative result. The prespecified secondary event-rate endpoints were multiplicity-controlled, meaning the analysis accounted for testing multiple outcomes. The different monitoring methods capture related events in different ways and should not be added together.

Patients entered with substantial disease burden: 68% reported daily hypoglycemic symptoms, 47% a history of loss of consciousness and 28% a history of hypoglycemia-related hospitalization. Those historical characteristics are not event rates during treatment. Completion was 45 of 47 participants assigned avexitide and 28 of 31 assigned placebo.

Amylyx said adverse events were mainly gastrointestinal or injection-site related and generally mild to moderate during the blinded period, with no deaths or treatment-related serious adverse events. The study's size and 16-week blinded duration limit what can be concluded about less common or longer-term risks. A 32-week open-label extension is ongoing and can add longer-duration experience, although it does not provide a concurrent placebo comparison.

From clinical benefit to patients reached

Amylyx estimates that approximately 160,000 people in the United States have PBH following the two most common bariatric procedures, Roux-en-Y gastric bypass and sleeve gastrectomy. Its disease-burden research also estimates that at least 30,000 require emergency department care or hospitalization. These are estimates of disease burden, not forecasts of patients who will be prescribed avexitide.

LUCIDITY studied adults after Roux-en-Y bypass with recurrent events despite dietary management. The 160,000 estimate also includes people who underwent sleeve gastrectomy, so it is broader than the population directly studied. The final FDA label, if approved, will determine the authorized population. Even within it, diagnosis, specialist access, documentation of events and reimbursement will affect how many patients start treatment.

Daily injection is another practical consideration for a chronic condition. The trial's high completion rate supports the feasibility of treatment in a closely monitored study, but routine persistence and access will need to be observed after any launch. The ongoing extension will add information about continued use, while the company develops AMX0318, a separate earlier-stage GLP-1 receptor antagonist intended for longer-acting administration.

The company's immediate development plan is to submit a new drug application by the end of 2026 and prepare for a possible U.S. launch in 2027 if approved. The FDA has granted avexitide breakthrough therapy designation for PBH. The timing and terms of any regulatory decision remain dependent on review of the complete submission.

Funding the launch after a share offering

At September 30, Amylyx held $768.1 million in cash, cash equivalents and marketable securities, up from $250.8 million at June 30. Much of the increase came from an August offering that generated approximately $544.6 million in net proceeds. The financing gives the company resources for launch preparation and manufacturing, while increasing the share count over which any future earnings will be spread.

The quarterly filing reports 16.2 million shares sold at $35.50 each, including the underwriters' option. That issuance equaled approximately 14.6% of the 111.4 million shares outstanding at June 30. That comparison uses the disclosed earlier share count for scale; options and other share movements mean it is not a precise calculation of an individual holder's dilution.

$ millionsQ3 2025Q3 2026
Research and development expense19.928.4
Selling, general and administrative expense16.221.3
Net loss(34.4)(45.5)

Research spending increased as Amylyx advanced avexitide and other programs. Selling, general and administrative costs rose with hiring and commercial preparation. These are group costs: the company does not allocate all personnel and similar expenses to individual development programs, so the figures do not establish avexitide's standalone operating economics.

For the first nine months of 2026, operating activities used $102.0 million, compared with a $130.2 million net loss. Noncash stock compensation of $24.8 million and a $4.0 million research milestone charge helped bridge the difference; changes in operating assets and liabilities provided a net $2.1 million. The associated $4.0 million milestone payment appears in investing cash flow, so it should not be overlooked when assessing total spending. The filing also disclosed $30.0 million of remaining unconditional manufacturing purchase obligations at September 30, expected through 2028.

The near-term issue has shifted from generating pivotal evidence to translating it into an approvable product and a reachable patient population. The year-end filing will establish the proposed regulatory scope. If approved, the number of diagnosed, eligible patients who obtain coverage and remain on treatment will determine whether the clinical event-rate reduction can support a durable commercial business.

This material is provided for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

Companies Discussed

About AER Insights

Alliance Equity Research publishes timely insights on company-specific developments, industry trends, capital markets activity, and emerging investment themes across global public markets, with a particular focus on undercovered companies, sectors, and developments that often receive limited attention from mainstream financial research. Our analysis focuses on the financial, strategic, and valuation implications behind the headlines, using company disclosures, filings, market data, and sector context to help investors understand what matters, why it matters, and what to watch next.

Get AER Insights by Email

Receive new AER Insights and research updates in your inbox.

Subscribe
Conceptual image of an unbranded nasal spray and a pulse oximeter on a clean surface.Biotechnology & Healthcare

Milestone Extends Its Cash Runway as CARDAMYST’s Early Sales Lag Launch Costs

Milestone Pharmaceuticals plans to cut operating expenses by approximately 30% as it develops a second potential use for CARDAMYST, its newly launched heart-rhythm nasal spray. Third-quarter product sales reached $963,000, while a separate $2 million licensing milestone accounted for most reported revenue. Management expects its cash to support operations into late 2028, around the time of a Phase 3 readout. Investors must weigh improving prescription activity and insurance coverage against launch spending, sales-based financing obligations and the time needed to establish a sustainable commercial business.

Alliance Equity ResearchNovember 14, 20267 min read
Read article
Conceptual aerial view of an open-pit mine with terraced earth and a winding haul road.Mining & Critical Minerals

Atalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital

Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.

Alliance Equity ResearchNovember 13, 20267 min read
Read article
Conceptual close-up illustration of red blood cells against a dark blue background.Biotechnology & Healthcare

Kura’s Leukemia Drug Sales Grow as Partnership and Financing Shape Future Returns

Kura Oncology’s first commercial medicine generated $13.9 million in third-quarter sales as more patients began treatment for a genetically defined form of acute myeloid leukemia. The launch is gaining traction, but Kura shares U.S. commercialization profits and losses with Kyowa Kirin and continues to fund extensive clinical development. A new Oberland Capital financing provides capital now and conditional access to more, alongside debt, equity issuance and a future sales-based obligation. The opportunity to treat newly diagnosed patients is larger than the current indication, but evidence from a Phase 3 program is not expected until 2028.

Alliance Equity ResearchNovember 12, 20268 min read
Read article
Offshore wind turbines in a line across the sea under a cloudy sky.Energy

RWE and KKR Share Capital Commitments as £12 Billion Wind Projects Advance

RWE and KKR have completed their partnership and secured financing for two British offshore wind farms requiring approximately £12 billion of investment. Each partner will own half of the projects, while RWE leads construction and delivery. Long-term power contracts provide greater revenue visibility, and project-level financing will help support development through expected commissioning in 2030. For investors, the transaction shares RWE’s capital commitments but leaves important details undisclosed, including the partners’ individual contributions. Construction costs, timing and electricity generation will determine how much value the projects ultimately deliver.

Alliance Equity ResearchNovember 11, 20266 min read
Read article
View all insights

About Alliance Equity Research

Alliance Equity Research publishes independent and company-sponsored equity research on undercovered, emerging, and high-potential public companies globally. Our analyst-built, model-backed research combines fundamental business analysis, financial forecasting, and valuation.

Email: info@alliancekp.com · Website: https://allianceequityresearch.com

For detailed company research, financial models, or coverage inquiries, contact our research team.

Research commentary for informational purposes. This document does not constitute personalized investment advice or a Buy, Hold, or Sell recommendation. For important disclosures, including information about research sponsorship and potential conflicts of interest, visit allianceequityresearch.com/disclosures.